118 related articles for article (PubMed ID: 37536559)
21. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Chen HD; Huang CS; Xu QC; Li F; Huang XT; Wang JQ; Li SJ; Zhao W; Yin XY
Int J Biol Sci; 2020; 16(7):1207-1217. PubMed ID: 32174795
[TBL] [Abstract][Full Text] [Related]
23. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
[TBL] [Abstract][Full Text] [Related]
24. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.
Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D
J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337
[TBL] [Abstract][Full Text] [Related]
25. A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m
Luo Y; He M; Yang J; Zhang F; Chen J; Wen X; Fan J; Fan X; Chai P; Jia R
Sci China Life Sci; 2023 Sep; 66(9):2138-2151. PubMed ID: 36949231
[TBL] [Abstract][Full Text] [Related]
26. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
[TBL] [Abstract][Full Text] [Related]
27. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
28. An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc-initiated retinoblastoma.
Singh HP; Shayler DWH; Fernandez GE; Thornton ME; Craft CM; Grubbs BH; Cobrinik D
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2200721119. PubMed ID: 35867756
[TBL] [Abstract][Full Text] [Related]
29. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
Zhong S; Zhang Y; Yin X; Di W
Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
[TBL] [Abstract][Full Text] [Related]
30. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
31. Secondary enucleated retinoblastoma with MYCN amplification.
Moulin AP; Stathopoulos C; Marcelli F; Schoumans Pouw J; Beck-Popovic M; Munier FL
Ophthalmic Genet; 2021 Jun; 42(3):354-359. PubMed ID: 33870828
[No Abstract] [Full Text] [Related]
32. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Rushlow DE; Mol BM; Kennett JY; Yee S; Pajovic S; Thériault BL; Prigoda-Lee NL; Spencer C; Dimaras H; Corson TW; Pang R; Massey C; Godbout R; Jiang Z; Zacksenhaus E; Paton K; Moll AC; Houdayer C; Raizis A; Halliday W; Lam WL; Boutros PC; Lohmann D; Dorsman JC; Gallie BL
Lancet Oncol; 2013 Apr; 14(4):327-34. PubMed ID: 23498719
[TBL] [Abstract][Full Text] [Related]
33. MRI Features for Identifying
Jansen RW; de Bloeme CM; Cardoen L; Göricke S; van Elst S; Jessen JL; Ramasubramanian A; Skalet AH; Miller AK; Maeder P; Uner OE; Hubbard GB; Grossniklaus H; Boldt HC; Nichols KE; Brennan RC; Sen S; Sirin S; Brisse HJ; Galluzzi P; Dommering CJ; Castelijns JA; van der Valk P; Boellaard R; Dorsman J; Moll AC; de Jong MC; de Graaf P
Radiology; 2023 Jun; 307(5):e222264. PubMed ID: 37191489
[TBL] [Abstract][Full Text] [Related]
34. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Zhong L; Yang S; Jia Y; Lei K
J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
[TBL] [Abstract][Full Text] [Related]
36. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
37. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
38. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Zhou Y; Lu L; Jiang G; Chen Z; Li J; An P; Chen L; Du J; Wang H
Cell Death Differ; 2019 Aug; 26(8):1442-1452. PubMed ID: 30451989
[TBL] [Abstract][Full Text] [Related]
39. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.
Gao Y; Volegova M; Nasholm N; Das S; Kwiatkowski N; Abraham BJ; Zhang T; Gray NS; Gustafson C; Krajewska M; George RE
Front Oncol; 2021; 11():773186. PubMed ID: 35198433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
